Repetitive Transcranial Magnetic Stimulation for Depression

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Depression+1 MoreRepetitive Transcranial Magnetic Stimulation - Device
Eligibility
22 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether using brain network connectivity patterns can help optimize outcomes from rTMS treatment for depression.

Eligible Conditions
  • Depression
  • Major Depressive Disorder

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Baseline and 1 Week Post Treatment (8-10 weeks)

Week 10
Change in depression, as measured by the Hamilton Depression Rating Scale (HAMD17)
Week 9
Change in depression, as measured by the Beck Depression Inventory (BDI-21)
Change in depression, as measured by the Quick Inventory of Depressive Symptomology (QIDS)
Week 9
Change in Resting State fMRI Connectivity

Trial Safety

Side Effects for

rTMS With Sensorimotor Retraining, Then rTMS With CTL
40%Decreased balance
20%Abnormal Sleep Pattern
20%Mood change
This histogram enumerates side effects from a completed 2015 Phase 1 & 2 trial (NCT01738581) in the rTMS With Sensorimotor Retraining, Then rTMS With CTL ARM group. Side effects include: Decreased balance with 40%, Abnormal Sleep Pattern with 20%, Mood change with 20%.

Trial Design

3 Treatment Groups

Opposite Side Arm
1 of 3
Standard of Care
1 of 3
Targeted Side Arm
1 of 3

Active Control

Experimental Treatment

348 Total Participants · 3 Treatment Groups

Primary Treatment: Repetitive Transcranial Magnetic Stimulation · No Placebo Group · Phase 3

Targeted Side Arm
Device
Experimental Group · 1 Intervention: Repetitive Transcranial Magnetic Stimulation · Intervention Types: Device
Opposite Side Arm
Device
ActiveComparator Group · 1 Intervention: Repetitive Transcranial Magnetic Stimulation · Intervention Types: Device
Standard of Care
Device
ActiveComparator Group · 1 Intervention: Repetitive Transcranial Magnetic Stimulation · Intervention Types: Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Repetitive Transcranial Magnetic Stimulation
2013
Completed Phase 3
~1130

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline and 1 week post treatment (8-10 weeks)

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,555 Previous Clinical Trials
1,823,411 Total Patients Enrolled
611 Trials studying Depression
242,386 Patients Enrolled for Depression
Weill Medical College of Cornell UniversityLead Sponsor
989 Previous Clinical Trials
1,338,582 Total Patients Enrolled
60 Trials studying Depression
15,484 Patients Enrolled for Depression
Conor Liston, MD, PhDPrincipal InvestigatorWeill Medical College of Cornell University
1 Previous Clinical Trials
300 Total Patients Enrolled
1 Trials studying Depression
300 Patients Enrolled for Depression

Eligibility Criteria

Age 22 - 65 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are taking a medication intended to treat depression or reduce symptoms of depression.
You have not responded to 1 antidepressant medication at an adequate dose and duration as measured by a modified Antidepressant Treatment History Form.
You have provided written consent to allow communication between members of the research team and the patient's outpatient clinician(s) (psychiatrist, psychotherapist, nurse practitioner, primary care physician, or equivalent) as needed to ensure safety.

Who else is applying?

What state do they live in?
New York70.0%
New Jersey20.0%
Wisconsin10.0%
How old are they?
18 - 65100.0%
What site did they apply to?
Weill Cornell Medicine100.0%
What portion of applicants met pre-screening criteria?
Met criteria90.0%
Did not meet criteria10.0%

How responsive is this trial?

Most responsive sites:
  1. Weill Cornell Medicine: < 24 hours
Typically responds via
Phone Call25.0%
Email75.0%
Average response time
  • < 2 Days